Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) Cost of Revenue (2016 - 2025)

AtriCure (ATRC) has disclosed Cost of Revenue for 16 consecutive years, with $35.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 11.07% to $35.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $133.7 million, a 13.56% increase, with the full-year FY2025 number at $133.7 million, up 13.56% from a year prior.
  • Cost of Revenue was $35.2 million for Q4 2025 at AtriCure, up from $32.9 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $35.2 million in Q4 2025 to a low of $14.7 million in Q1 2021.
  • A 5-year average of $25.2 million and a median of $24.2 million in 2023 define the central range for Cost of Revenue.
  • Biggest YoY gain for Cost of Revenue was 31.34% in 2021; the steepest drop was 2.75% in 2021.
  • AtriCure's Cost of Revenue stood at $18.2 million in 2021, then increased by 25.89% to $22.9 million in 2022, then rose by 16.64% to $26.7 million in 2023, then grew by 18.45% to $31.7 million in 2024, then grew by 11.07% to $35.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's Cost of Revenue are $35.2 million (Q4 2025), $32.9 million (Q3 2025), and $34.7 million (Q2 2025).